St. Louis, MO – December 4, 2012 – Westport Pharmaceuticals, a St. Louis-based, specialty pharmaceutical company focused on OTC consumer healthcare products with abuse deterrent technology, announced today the arrival of Zephrex-D™, a tamper-resistant pseudoephedrine-based decongestant, now available in retail stores throughout the St. Louis region and the state of Missouri. The unique formulation of Zephrex-D provides powerful decongestant relief for consumers while protecting against the illicit manufacture of methamphetamine. Being safe and effective, and having the added benefit of tamper-resistance, Zephrex-D represents a tremendous breakthrough in the battle against methamphetamine production without needing to restrict access for legitimate consumers.
Methamphetamine has become a tremendous challenge for the entire nation with meth labs and abuse at epidemic proportions in Missouri and across all of America. The number of clandestine and mobile meth lab seizures in Missouri has increased by 50% in the last four years, and the cost to the state for law enforcement, prosecution, incarceration and site clean-up efforts is estimated to be over $5 million annually. As Paul Hemings, the Vice President and General Manager of Westport explains, “The arrival of Zephrex-D is an integral part of a comprehensive solution to help end meth labs and meth-related crime in our local communities, throughout Missouri and ultimately, across our country.” Missouri is the ideal location to launch Zephrex-D and build awareness for a product that is formulated to block all commonly known methods of meth making, while maintaining full decongestant benefits and relief for patients.
Several national and regional retailers are now stocking Zephrex-D throughout St. Louis and Missouri. Because it is a pseudoephedrine-based product, it will be available behind the pharmacy counter and subject to all existing Federal, State and local purchase restrictions for now. Some local ordinances require prescriptions to purchase pseudoephedrine products, but Zephrex-D has been exempted from the prescription requirement in several instances. For a listing of participating retailers and their locations, please visit www.Zephrex-D.com . These pharmacies are being educated on the benefits of Zephrex-D and will be ready to address consumer inquiries. Together with retailer support, Westport plans to generate consumer acceptance for Zephrex-D and expand distribution nationally within the next year.
The introduction of Zephrex-D marks a significant step towards improving the security and delivery of pseudoephedrine. Delivering the drug in this formulation prevents the illicit meth-making process without further encumbering access for those consumers seeking therapeutic relief from sinus congestion and pressure. It is a win for patients, our communities and all those who are dedicated to protecting and making our neighborhoods a safe place to live.
For more information, please visit www.zephrex-d.com.